{"chunk_id": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue__chunk_8", "source": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue", "text": "current pregnancy letter category. For drugs that are \nabsorbed systemically, the “Risk Summary” must include statements based on the risk of adverse \ndevelopmental outcomes from all relevant data sou rces.  When there is relevant information to \nhelp health care providers make prescribing decisions and counsel women about the use of the \ndrug during pregnancy, it is included under a new heading  called Clinical Considerations.  This \ncould include informati on on disease- associated maternal an"}